Extensively Drug-Resistant Tuberculosis: Report and Literature Review on Two Cases Requiring Prolonged Treatment

Overview

Journal Am J Case Rep

Specialty General Medicine

Date 2016 Nov 4

PMID 27807339

Authors

Martha Matos-Tocasca

Gabriel De La Cruz-Ku

Erick Auccacusi

Diego Fernandez-Salas

Tatiana Garcia-Ahuanari

Bryan Valcarcel-Valdivia

Affiliations

Soon will be listed here.

Abstract

BACKGROUND Extensively drug-resistant tuberculosis (XDR-TB) is a global problem due to the high morbidity and mortality it causes. Peru is one of the countries with the highest numbers of cases of XDR-TB, which increase every year. CASE REPORT We present the case of two siblings who developed XDR-TB, underwent surgery twice, and were in individualized treatment for more than 6 years. Finally they achieved remission of symptoms, despite not having standardized treatment schemes during their diagnosis period. CONCLUSIONS Extensively drug-resistant tuberculosis can be cured with a treatment that involves both medical care and patient actions to achieve remission of the disease.

References

Ramu G, Iyer G . Side effects of clofazimine therapy. Lepr India. 1976; 48(4 Suppl):722-31. View

Parmet W . Legal power and legal rights--isolation and quarantine in the case of drug-resistant tuberculosis. N Engl J Med. 2007; 357(5):433-5. DOI: 10.1056/NEJMp078133. View

ODonnell M, Padayatchi N, Kvasnovsky C, Werner L, Master I, Horsburgh Jr C . Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection. Emerg Infect Dis. 2013; 19(3):416-24. PMC: 3647656. DOI: 10.3201/eid1903.120998. View

Porco T, Getz W . Controlling extensively drug-resistant tuberculosis. Lancet. 2007; 370(9597):1464-5. DOI: 10.1016/S0140-6736(07)61614-6. View

Zumla A, Nahid P, Cole S . Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov. 2013; 12(5):388-404. DOI: 10.1038/nrd4001. View

Job C, Yoder L, Jacobson R, Hastings R . Skin pigmentation from clofazimine therapy in leprosy patients: a reappraisal. J Am Acad Dermatol. 1990; 23(2 Pt 1):236-41. DOI: 10.1016/0190-9622(90)70204-u. View

Porwal C, Kaushik A, Makkar N, Banavaliker J, Hanif M, Singla R . Incidence and risk factors for extensively drug-resistant tuberculosis in Delhi region. PLoS One. 2013; 8(2):e55299. PMC: 3563594. DOI: 10.1371/journal.pone.0055299. View

Madansein R, Parida S, Padayatchi N, Singh N, Master I, Naidu K . Surgical treatment of complications of pulmonary tuberculosis, including drug-resistant tuberculosis. Int J Infect Dis. 2015; 32:61-7. DOI: 10.1016/j.ijid.2015.01.019. View

. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol Rec. 2006; 81(45):430-2. View

10.

Wang X, Ma A, Han X, Gu X, Fu L, Li P . Correlations between drug resistance of Beijing/W lineage clinical isolates of Mycobacterium tuberculosis and sublineages: a 2009-2013 prospective study in Xinjiang province, China. Med Sci Monit. 2015; 21:1313-8. PMC: 4434980. DOI: 10.12659/MSM.892951. View

11.

Zhang Q, Wu Z, Zhang Z, Sha W, Shen X, Xiao H . Efficacy and effect of free treatment on multidrug-resistant tuberculosis. Exp Ther Med. 2016; 11(3):777-782. PMC: 4774331. DOI: 10.3892/etm.2015.2966. View

12.

Mekonnen F, Tessema B, Moges F, Gelaw A, Eshetie S, Kumera G . Multidrug resistant tuberculosis: prevalence and risk factors in districts of metema and west armachiho, Northwest Ethiopia. BMC Infect Dis. 2015; 15:461. PMC: 4624367. DOI: 10.1186/s12879-015-1202-7. View

13.

POTTER J, Inamdar L, Okereke E, Collinson S, Dukes R, Mandelbaum M . Support of vulnerable patients throughout TB treatment in the UK. J Public Health (Oxf). 2015; 38(2):391-5. DOI: 10.1093/pubmed/fdv052. View

14.

Van der Walt M, Lancaster J, Odendaal R, Davis J, Shean K, Farley J . Serious treatment related adverse drug reactions amongst anti-retroviral naïve MDR-TB patients. PLoS One. 2013; 8(4):e58817. PMC: 3615995. DOI: 10.1371/journal.pone.0058817. View

15.

Padayatchi N, Gopal M, Naidoo R, Werner L, Naidoo K, Master I . Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study. J Antimicrob Chemother. 2014; 69(11):3103-7. PMC: 4195472. DOI: 10.1093/jac/dku235. View

16.

Gandhi N, Moll A, Sturm A, Pawinski R, Govender T, Lalloo U . Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006; 368(9547):1575-80. DOI: 10.1016/S0140-6736(06)69573-1. View

17.

Connor S, Foley K, Harding R, Jaramillo E . Declaration on palliative care and MDR/XDR-TB. Int J Tuberc Lung Dis. 2012; 16(6):712-3. DOI: 10.5588/ijtld.12.0267. View

18.

Falzon D, Gandhi N, Migliori G, Sotgiu G, Cox H, Holtz T . Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J. 2012; 42(1):156-68. PMC: 4487776. DOI: 10.1183/09031936.00134712. View

19.

Djuardi Y, Sartono E, Wibowo H, Supali T, Yazdanbakhsh M . A longitudinal study of BCG vaccination in early childhood: the development of innate and adaptive immune responses. PLoS One. 2010; 5(11):e14066. PMC: 2988815. DOI: 10.1371/journal.pone.0014066. View

20.

Siroka A, Ponce N, Lonnroth K . Association between spending on social protection and tuberculosis burden: a global analysis. Lancet Infect Dis. 2016; 16(4):473-9. PMC: 4834192. DOI: 10.1016/S1473-3099(15)00401-6. View